For tens of millions of people with overactive bladder, the choice has often been stark: manage disruptive symptoms with medications that carry side effects, or consider an invasive surgical implant. EBT Medical, a Toronto-based clinical-stage company, is betting there is a third way, one that rests on stimulating a specific nerve in the leg that most people have never heard of [EBT Medical].
The Saphenous Nerve Wedge
EBT's lead product, called NiNA, is a non-invasive neurostimulator designed to target the saphenous nerve for the treatment of overactive bladder [EBT Medical]. The company's foundational intellectual property, spun out from the University of Toronto in 2014, centers on the novel use of this nerve as a gateway to pelvic health function [EBT Medical]. This approach seeks to offer an alternative that sits between first-line pharmacotherapy and more aggressive interventions like sacral nerve stimulation, which requires an implanted device. The bet is that a convenient, external device can deliver meaningful symptom relief without the systemic side effects of drugs or the procedural risks of surgery.
A Team Built for Regulated Hardware
The company's leadership reflects the long, regulated pathway of bringing a new medical device to patients. CEO and co-founder Keith R. Carlton brings over two decades of experience in neuromodulation and pelvic health from industry giants Medtronic and Boston Scientific [EBT Medical]. In late 2020, the company bolstered its research efforts by hiring Mike Labbe as Vice President of R&D, another veteran with deep neuromodulation experience [EBT Medical, Nov 2020]. This team composition is a deliberate signal to investors and future regulatory reviewers that EBT understands the rigor required for clinical validation and eventual FDA clearance.
| Role | Name | Key Background |
|---|---|---|
| CEO & Co-Founder | Keith R. Carlton | 20+ years at Medtronic & Boston Scientific in neuromodulation/pelvic health [EBT Medical] |
| Co-Founder | Paul Yoo | University of Toronto professor who discovered and patented the saphenous nerve approach [EBT Medical] |
| VP of R&D | Mike Labbe | Joined Nov 2020 with prior neuromodulation experience [EBT Medical, Nov 2020] |
The Long Road from Series A
EBT Medical secured its primary war chest in 2020, closing a $10 million Series A round co-led by SV Health Investors and Genesys Capital [Crunchbase, Circa 2020]. The capital was earmarked for further technology development, gathering clinical data, and team expansion [SV Health Investors, November 18, 2019]. Since that round, however, the public record on clinical progress or regulatory milestones has grown quiet. The company was an award winner in the 2018 MassChallenge cohort, but the leap from accelerator prize to pivotal clinical trial is a significant one [EBT Medical, Sept 2018] [EBT Medical, Oct 2018]. For a hardware-therapeutics startup, the years following a Series A are typically consumed by costly and time-consuming clinical studies, a phase where visibility is low but execution risk is high.
The Competitive and Clinical Hurdles
The market EBT aims to enter is dominated by established players with deep commercial footprints. Medtronic is a titan in sacral neuromodulation, and companies like Axonics have successfully commercialized less invasive implantable devices. EBT's differentiation hinges entirely on the clinical validity of its saphenous nerve target and the patient appeal of a truly non-invasive form factor. Without published, peer-reviewed data demonstrating safety and efficacy, the technology remains an intriguing hypothesis. The company's success will be determined by a few critical, unanswered questions.
- Clinical validation. The core premise requires robust clinical trial results to prove it can reduce incontinence episodes and improve quality of life as intended.
- Regulatory pathway. Navigating the FDA's De Novo or 510(k) clearance process for a novel nerve target will be a complex and resource-intensive endeavor.
- Commercial timing. Even with approval, the company would need to build a commercial organization to compete with giants who have entrenched relationships with urologists and payers.
The patient population here is clear: adults with overactive bladder, a condition characterized by a sudden, uncontrollable urge to urinate that can significantly disrupt daily life. The current standard of care often begins with behavioral modifications, then progresses to a trial of anticholinergic or beta-3 agonist medications, which are linked to side effects like dry mouth, dizziness, and constipation [EBT Medical]. For those who don't respond to or tolerate drugs, the next steps involve more invasive procedures, such as percutaneous tibial nerve stimulation or implantable sacral nerve stimulators. EBT Medical's ambition is to insert its NiNA device earlier into this treatment algorithm, offering a drug-free, non-surgical option that patients can use at home. The next twelve months will be telling; the company will need to break its silence with tangible clinical progress to show its $10 million bet is on a path to becoming a real therapeutic alternative.
Sources
- [EBT Medical, Unknown] EBT Medical & NiNA - Reimagining the Treatment of Pelvic Health Disorders | https://ebtmedical.com/
- [EBT Medical, Nov 2020] Mike Labbe Joins EBT Medical as Vice President of Research & Development | https://ebtmedical.com/mike-labbe-joins-ebt-medical-as-vice-president-of-research-development/
- [Crunchbase, Circa 2020] EBT Medical - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/ebt-medical
- [SV Health Investors, November 18, 2019] EBT Secures USD$10M Series A - SV Health Investors | https://svhealthinvestors.com/news/ebt-secures-usd-10m-series-a
- [EBT Medical, Sept 2018] EBT Medical, Inc. Named a Top 26 Startup by MassChallenge Boston | https://ebtmedical.com/ebt-medical-inc-named-a-top-26-startup-by-masschallenge-boston/
- [EBT Medical, Oct 2018] EBT Wins $100K Cash Prize from MassChallenge | https://ebtmedical.com/ebt-wins-100k-cash-prize-from-masschallenge-at-its-annual-awards/